Shukra Pharmaceuticals (524632) Q2 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 25/26 earnings summary
13 Nov, 2025Executive summary
Board approved unaudited financial results for the quarter and half year ended September 30, 2025, and reviewed business operations.
Statutory auditors provided an unqualified review opinion on the results.
Financial highlights
Revenue from operations for Q2 FY26 was ₹587.74 lakhs, up from ₹555.52 lakhs in Q2 FY25.
Net profit for Q2 FY26 stood at ₹237.81 lakhs, compared to ₹53.89 lakhs in Q2 FY25.
Total income for H1 FY26 was ₹1,409.08 lakhs, with net profit at ₹340.77 lakhs.
Earnings per share (EPS) for Q2 FY26 was ₹0.05, up from ₹0.02 in Q2 FY25.
Key financial ratios and metrics
Gross margin improved due to higher revenue and controlled expenses.
Equity share capital remained at ₹4,378.79 lakhs.
Other equity increased to ₹2,201.78 lakhs as of September 30, 2025.
Latest events from Shukra Pharmaceuticals
- Sales and exports surged, but higher depreciation cut profit as injectable expansion advanced.524632
Q4 96/97 - Sales grew 18%, profit rose, and injectable production was poised to begin amid operating cash outflow.524632Q4 97/98
- Sales and exports surged as expansion funding coincided with negative operating cash flow.524632Q4 99/00
- Turnover rose 22.72%; injection-plant launch awaited regulatory approval.524632Q4 98/99
- Higher sales, lower PAT after a ₹5.65m write-off, and restructuring define FY16.524632Q4 15/16
- Revenue surged, but profit collapsed amid qualified audit and compliance concerns.524632Q4 19/20
- Revenue and profit surged; net debt turned negative and a ₹1 dividend was proposed.524632Q4 23/24
- FY23 earnings surged as export growth advanced alongside higher receivables and tax exposure.524632Q4 22/23
- A bank settlement lifted FY12 profit despite declining revenue and restructuring pressures.524632Q4 11/12
- Revenue declined, losses deepened, and restructuring remained central to the outlook.524632Q4 12/13